EA031906B1 - Твердая пероральная лекарственная форма миртазапина и тизанидина для лечения болевого расстройства - Google Patents

Твердая пероральная лекарственная форма миртазапина и тизанидина для лечения болевого расстройства Download PDF

Info

Publication number
EA031906B1
EA031906B1 EA201591603A EA201591603A EA031906B1 EA 031906 B1 EA031906 B1 EA 031906B1 EA 201591603 A EA201591603 A EA 201591603A EA 201591603 A EA201591603 A EA 201591603A EA 031906 B1 EA031906 B1 EA 031906B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pain
mirtazapine
tizanidine
dosage form
solid oral
Prior art date
Application number
EA201591603A
Other languages
English (en)
Russian (ru)
Other versions
EA201591603A1 (ru
Inventor
Маргарита Алексеевна МОРОЗОВА
Аллан Герович БЕНИАШВИЛИ
Максим Эдуардович ЗАПОЛЬСКИЙ
Original Assignee
Общество С Ограниченной Ответственностью "Валента-Интеллект"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Валента-Интеллект" filed Critical Общество С Ограниченной Ответственностью "Валента-Интеллект"
Publication of EA201591603A1 publication Critical patent/EA201591603A1/ru
Publication of EA031906B1 publication Critical patent/EA031906B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201591603A 2013-03-22 2014-03-17 Твердая пероральная лекарственная форма миртазапина и тизанидина для лечения болевого расстройства EA031906B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013112747/15A RU2509560C1 (ru) 2013-03-22 2013-03-22 Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
PCT/RU2014/000165 WO2014148951A1 (fr) 2013-03-22 2014-03-17 Nouvelle combinaisons thérapeutiques de mirtazapine destinées à s'utiliser en cas de troubles douloureux

Publications (2)

Publication Number Publication Date
EA201591603A1 EA201591603A1 (ru) 2016-01-29
EA031906B1 true EA031906B1 (ru) 2019-03-29

Family

ID=50279596

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591603A EA031906B1 (ru) 2013-03-22 2014-03-17 Твердая пероральная лекарственная форма миртазапина и тизанидина для лечения болевого расстройства

Country Status (7)

Country Link
CN (1) CN105209044B (fr)
EA (1) EA031906B1 (fr)
HK (1) HK1214156A1 (fr)
MY (1) MY180772A (fr)
RU (1) RU2509560C1 (fr)
UA (1) UA112726C2 (fr)
WO (1) WO2014148951A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2705375C2 (ru) * 2014-01-21 2019-11-07 Вокхардт Лимитед Фармацевтические композиции, содержащие антибактериальные агенты
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
WO2018197932A1 (fr) * 2017-04-27 2018-11-01 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques de kétorolac
RU2736713C1 (ru) * 2019-12-02 2020-11-19 Общество С Ограниченной Ответственностью "Валента - Интеллект" Комбинация миртазапина и тизанидина для применения при болевых расстройствах

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020076A1 (en) * 2006-07-21 2008-01-24 Khem Jhamandas Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020076A1 (en) * 2006-07-21 2008-01-24 Khem Jhamandas Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KALIKSTA® (Calixta). Instruktsia po primeneniju, protivopokazania i sostav. Entsiklopedia RLS® № LP-001110 dated 03.11.2011 [on-line], [retrieved on 18.06.2014]. Found in Internet: <URL: http://www.rlsnet.ra/tn_index_id_50150.htm>, p. 1-3 *
SIRDALUD® (Sirdalud®). Instruktsia po primeneniju, protivopokazania i sostav. Entsiklopedia RLS® № PN012947/01 dated 03.08.2010 [on-line], [retrieved on 19.06.2014]. Found in Internet: <URL: http://www.rlsnet.ra/tn_index_id_2924.htm>, p. 1-7 *

Also Published As

Publication number Publication date
HK1214156A1 (zh) 2016-07-22
CN105209044B (zh) 2017-08-15
RU2509560C1 (ru) 2014-03-20
CN105209044A (zh) 2015-12-30
EA201591603A1 (ru) 2016-01-29
WO2014148951A1 (fr) 2014-09-25
MY180772A (en) 2020-12-09
UA112726C2 (uk) 2016-10-10

Similar Documents

Publication Publication Date Title
Mercadante et al. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study
JP4633262B2 (ja) 心的外傷後ストレス障害、強迫性障害および関連する神経精神医学的障害の処置
AU2002311784B8 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EA006384B1 (ru) Композиция фентанила для интраназального введения
AU2002311784A1 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
Smiley et al. Dexmedetomidine sedation with and without midazolam for third molar surgery
JP2016537322A (ja) Trpa1アンタゴニスト及び鎮痛剤を含む医薬組成物
RU2509560C1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および/または神経精神医学的障害を改善するための4−アミノピリジンの使用
JP7264813B2 (ja) 末梢神経障害性疼痛の治療に使用するための局所作用用フェニトイン
Khan et al. Effect of gabapentin on opioid requirements in patients undergoing total abdominal hysterectomy
AU2016303610A1 (en) Combination therapy using acamprosate and D-cycloserine
US20060084659A1 (en) Augmentation of psychotherapy with cannabinoid reuptake inhibitors
Bufalari et al. Preemptive carprofen for peri-operative analgesia in dogs undergoing Tibial Plateau Leveling Osteotomy (TPLO): a prospective, randomized, blinded, placebo controlled clinical trial
EP2138174A1 (fr) Composition pharmaceutique sous forme de comprimé sublingual comprenant un anti-inflammatoire non stéroïdien et un analgésique opiacé pour la gestion de la douleur
ES2649491T3 (es) (R)-pirlindol y sus sales farmacéuticamente aceptables para uso en medicina
CZ20021116A3 (cs) Synergické kombinace antagonisty receptoru NK1 a strukturálního analogu GABA
WO2005105120A2 (fr) Combinaison pharmaceutique agissant sur le fonctionnement du systeme nerveux central (snc); procede de correction d&#39;etats associes a des troubles fonctionnels du snc; ensemble de produits pharmaceutiques; agent facilitant la penetration de la barriere hematoencephalique par des substances medicinales et/ou des metabolites;
Visser et al. Salmon calcitonin in the treatment of post herpetic neuralgia
DOURADO et al. Treatment of chronic pain in dentistry using anticonvulsants
Chaudhary et al. Rationalized approach for the treatment of neuropathic pain
Saarma Trazodone—a review of literature
WO2008010768A1 (fr) Méthode de traitement et de diagnostic du syndrome des jambes sans repos et de mouvements involontaires des membres pendant le sommeil et moyen pour la mise en oeuvre de ladite méthode
BR112020016672A2 (pt) Leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma e método de reduzir, inibir ou eliminar um ou mais sintomas de síndrome das pernas inquietas (rls) em um indivíduo em necessidade do mesmo
BR112019022175A2 (pt) Composições e método para tratamento de depressão